Please enable JavaScript to continue using this application.

Compare $RNA vs $TNXP | Chartloom

Compare

$RNA vs $TNXP

Atrium Therapeutics Inc · Tonix Pharmaceuticals Holding Corp

RNA

Atrium Therapeutics Inc

TNXP

Tonix Pharmaceuticals Holding Corp

Compare $RNA vs $TNXP

Comparing Atrium Therapeutics Inc and Tonix Pharmaceuticals Holding Corp

RNAAtrium Therapeutics Inc

TNXPTonix Pharmaceuticals Holding Corp

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

TNXPTonix Pharmaceuticals Holding Corp

Market cap

$116M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.39x

Rev growth (TTM)

196.0%

YTD performance

-55.9%

52W performance

-67.5%

FCF yield

-135.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNA

TNXP

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

TNXP

Tonix Pharmaceuticals Holding Corp

Market Cap

RNA$144M

TNXP$116M

Enterprise Value

RNA$71M

TNXP$-60M

Price

RNA$8.40

TNXP$7.30

P/E Ratio

RNAN/A

TNXPN/A

P/S Ratio

RNA3.48x

TNXP4.00x

EV/Sales

RNA1.73x

TNXP-2.06x

EV/EBITDA

RNA0.00x

TNXP0.00x

P/B Ratio

RNA0.63x

TNXP0.69x

P/FCF Ratio

RNAN/A

TNXPN/A

EV/FCF

RNA-0.89x

TNXP0.38x

PEG Ratio

RNAN/A

TNXPN/A

Forward P/E (NTM)

RNAN/A

TNXPN/A

Forward P/S (NTM)

RNAN/A

TNXP1.39x

Revenue (TTM)

RNA$41M

TNXP$29M

Revenue Growth (YoY)

RNA22.0%

TNXP196.0%

Forward Rev Growth

RNA-94.2%

TNXP101.6%

Gross Margin (TTM)

RNA0.0%

TNXP83.8%

Operating Margin (TTM)

RNA0.0%

TNXP0.0%

EBITDA Margin (TTM)

RNA-215.0%

TNXP-561.1%

Net Margin (TTM)

RNA-209.2%

TNXP-548.6%

FCF Margin (TTM)

RNA-193.4%

TNXP-543.3%

Net Income (TTM)

RNA$-86M

TNXP$-160M

FCF (TTM)

RNA$-80M

TNXP$-158M

EPS (TTM)

RNA-$5.05

TNXP-$9.60

ROE (TTM)

RNA-4030.0%

TNXP-6899.0%

ROA (TTM)

RNA-5864.0%

TNXP-6132.0%

ROIC (TTM)

RNA-4433.7%

TNXP-6899.0%

Cash

RNA$72M

TNXP$176M

Debt

RNA$0

TNXP$0

Net Cash/Debt

RNA$72M

TNXP$176M

Current Ratio (TTM)

RNA8.73x

TNXP6.61x

Quick Ratio (TTM)

RNA8.59x

TNXP6.13x

Debt/Equity (TTM)

RNA0.00x

TNXP0.00x

Debt/Assets (TTM)

RNA0.0%

TNXP0.0%

Interest Coverage (TTM)

RNAN/A

TNXPN/A

Net Debt/EBITDA (TTM)

RNA0.00x

TNXP0.00x

Beta

RNA1.20

TNXP1.87

52W Performance

RNA-82.6%

TNXP-67.5%

YTD Performance

RNA-88.3%

TNXP-55.9%

% from 52W High

RNA-88.5%

TNXP-68.3%

% from 52W Low

RNA10.1%

TNXP3.0%

Asset Turnover (TTM)

RNA0.28x

TNXP0.11x

FCF Yield (TTM)

RNA-55.5%

TNXP-135.9%

Earnings Yield (TTM)

RNA-60.1%

TNXP-137.2%

Dividend Yield (TTM)

RNAN/A

TNXPN/A

Rule of 40

RNA-171.3

TNXP-347.3

EV/GP/RG

RNAN/A

TNXPN/A

Ticker research

View RNA research View TNXP research

Metric	RNA Atrium Therapeutics Inc	TNXP Tonix Pharmaceuticals Holding Corp
Market & Valuation
Market Cap	$144M	$116M
Enterprise Value	$71M	$-60M
Price	$8.40	$7.30
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	4.00x
EV/Sales	1.73x	-2.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.63x	0.69x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	0.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.39x
Revenue & Growth
Revenue (TTM)	$41M	$29M
Revenue Growth (YoY)	22.0%	196.0%
Forward Rev Growth	-94.2%	101.6%
Profitability
Gross Margin (TTM)	0.0%	83.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	-561.1%
Net Margin (TTM)	-209.2%	-548.6%
FCF Margin (TTM)	-193.4%	-543.3%
Net Income (TTM)	$-86M	$-160M
FCF (TTM)	$-80M	$-158M
EPS (TTM)	-$5.05	-$9.60
ROE (TTM)	-4030.0%	-6899.0%
ROA (TTM)	-5864.0%	-6132.0%
ROIC (TTM)	-4433.7%	-6899.0%
Financial Health
Cash	$72M	$176M
Debt	$0	$0
Net Cash/Debt	$72M	$176M
Current Ratio (TTM)	8.73x	6.61x
Quick Ratio (TTM)	8.59x	6.13x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.87
52W Performance	-82.6%	-67.5%
YTD Performance	-88.3%	-55.9%
% from 52W High	-88.5%	-68.3%
% from 52W Low	10.1%	3.0%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.11x
FCF Yield (TTM)	-55.5%	-135.9%
Earnings Yield (TTM)	-60.1%	-137.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	-347.3
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View TNXP research

Valuation

P/S Ratio

RNA

3.48x

TNXP

4.00x

EV/FCF

RNA

-0.89x

TNXP

0.38x

Growth & revenue

Revenue Growth TTM

TNXP

196.0%

RNA

22.0%

Forward Revenue Growth

TNXP

101.6%

RNA

-94.2%

Profitability & performance

Gross Margin

TNXP

83.8%

RNA

0.0%

ROE

RNA

-4030.0%

TNXP

-6899.0%

FCF Yield %

RNA

-55.5%

TNXP

-135.9%

52-Week Performance

TNXP

-67.5%

RNA

-82.6%

Detailed metrics comparison

RNA

Atrium Therapeutics Inc

TNXP

Tonix Pharmaceuticals Holding Corp

Market Cap

RNA$144M

TNXP$116M

Enterprise Value

RNA$71M

TNXP$-60M

Price

RNA$8.40

TNXP$7.30

P/E Ratio

RNAN/A

TNXPN/A

P/S Ratio

RNA3.48x

TNXP4.00x

EV/Sales

RNA1.73x

TNXP-2.06x

EV/EBITDA

RNA0.00x

TNXP0.00x

P/B Ratio

RNA0.63x

TNXP0.69x

P/FCF Ratio

RNAN/A

TNXPN/A

EV/FCF

RNA-0.89x

TNXP0.38x

PEG Ratio

RNAN/A

TNXPN/A

Forward P/E (NTM)

RNAN/A

TNXPN/A

Forward P/S (NTM)

RNAN/A

TNXP1.39x

Revenue (TTM)

RNA$41M

TNXP$29M

Revenue Growth (YoY)

RNA22.0%

TNXP196.0%

Forward Rev Growth

RNA-94.2%

TNXP101.6%

Gross Margin (TTM)

RNA0.0%

TNXP83.8%

Operating Margin (TTM)

RNA0.0%

TNXP0.0%

EBITDA Margin (TTM)

RNA-215.0%

TNXP-561.1%

Net Margin (TTM)

RNA-209.2%

TNXP-548.6%

FCF Margin (TTM)

RNA-193.4%

TNXP-543.3%

Net Income (TTM)

RNA$-86M

TNXP$-160M

FCF (TTM)

RNA$-80M

TNXP$-158M

EPS (TTM)

RNA-$5.05

TNXP-$9.60

ROE (TTM)

RNA-4030.0%

TNXP-6899.0%

ROA (TTM)

RNA-5864.0%

TNXP-6132.0%

ROIC (TTM)

RNA-4433.7%

TNXP-6899.0%

Cash

RNA$72M

TNXP$176M

Debt

RNA$0

TNXP$0

Net Cash/Debt

RNA$72M

TNXP$176M

Current Ratio (TTM)

RNA8.73x

TNXP6.61x

Quick Ratio (TTM)

RNA8.59x

TNXP6.13x

Debt/Equity (TTM)

RNA0.00x

TNXP0.00x

Debt/Assets (TTM)

RNA0.0%

TNXP0.0%

Interest Coverage (TTM)

RNAN/A

TNXPN/A

Net Debt/EBITDA (TTM)

RNA0.00x

TNXP0.00x

Beta

RNA1.20

TNXP1.87

52W Performance

RNA-82.6%

TNXP-67.5%

YTD Performance

RNA-88.3%

TNXP-55.9%

% from 52W High

RNA-88.5%

TNXP-68.3%

% from 52W Low

RNA10.1%

TNXP3.0%

Asset Turnover (TTM)

RNA0.28x

TNXP0.11x

FCF Yield (TTM)

RNA-55.5%

TNXP-135.9%

Earnings Yield (TTM)

RNA-60.1%

TNXP-137.2%

Dividend Yield (TTM)

RNAN/A

TNXPN/A

Rule of 40

RNA-171.3

TNXP-347.3

EV/GP/RG

RNAN/A

TNXPN/A

Ticker research

View RNA research View TNXP research

Metric	RNA Atrium Therapeutics Inc	TNXP Tonix Pharmaceuticals Holding Corp
Market & Valuation
Market Cap	$144M	$116M
Enterprise Value	$71M	$-60M
Price	$8.40	$7.30
P/E Ratio	N/A	N/A
P/S Ratio	3.48x	4.00x
EV/Sales	1.73x	-2.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.63x	0.69x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.89x	0.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.39x
Revenue & Growth
Revenue (TTM)	$41M	$29M
Revenue Growth (YoY)	22.0%	196.0%
Forward Rev Growth	-94.2%	101.6%
Profitability
Gross Margin (TTM)	0.0%	83.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-215.0%	-561.1%
Net Margin (TTM)	-209.2%	-548.6%
FCF Margin (TTM)	-193.4%	-543.3%
Net Income (TTM)	$-86M	$-160M
FCF (TTM)	$-80M	$-158M
EPS (TTM)	-$5.05	-$9.60
ROE (TTM)	-4030.0%	-6899.0%
ROA (TTM)	-5864.0%	-6132.0%
ROIC (TTM)	-4433.7%	-6899.0%
Financial Health
Cash	$72M	$176M
Debt	$0	$0
Net Cash/Debt	$72M	$176M
Current Ratio (TTM)	8.73x	6.61x
Quick Ratio (TTM)	8.59x	6.13x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.87
52W Performance	-82.6%	-67.5%
YTD Performance	-88.3%	-55.9%
% from 52W High	-88.5%	-68.3%
% from 52W Low	10.1%	3.0%
Efficiency & Yields
Asset Turnover (TTM)	0.28x	0.11x
FCF Yield (TTM)	-55.5%	-135.9%
Earnings Yield (TTM)	-60.1%	-137.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-171.3	-347.3
EV/GP/RG	N/A	N/A
Ticker research	View RNA research	View TNXP research